tiprankstipranks
VYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trial
PremiumThe FlyVYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trial
2M ago
VYNE Therapeutics Sees Strong Shareholder Support for Growth
Premium
Company Announcements
VYNE Therapeutics Sees Strong Shareholder Support for Growth
2M ago
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential
Premium
The Fly
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential
3M ago
VYNE Therapeutics sees cash runway through end of 2025
PremiumThe FlyVYNE Therapeutics sees cash runway through end of 2025
6M ago
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year
Premium
The Fly
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year
6M ago
Vyne Therapeutics Inc (VYNE) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Vyne Therapeutics Inc (VYNE) Q2 Earnings Cheat Sheet
7M ago
VYNE Therapeutics expects cash to fund operations through 2025
PremiumThe FlyVYNE Therapeutics expects cash to fund operations through 2025
10M ago
VYNE Therapeutics reports Q1 EPS (15c) vs. ($1.74) last year
Premium
The Fly
VYNE Therapeutics reports Q1 EPS (15c) vs. ($1.74) last year
10M ago
VYNE Therapeutics announces FDA clearance of IND application for VYN202
Premium
The Fly
VYNE Therapeutics announces FDA clearance of IND application for VYN202
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100